Aminoglycoside antibiotics as first-line treatment of acute appendicitis and cholecystitis

References

• Sartelli M, Chichom-Mefire A, Labricciosa FM, et al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg. 2017;12(1):29. doi: 10.1186/s13017-017-0141-6.
   PubMedGoogle Scholar
• Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. N Engl J Med. 2015;72(21):1996–2005. doi: 10.1056/NEJMoa1411162.
   Google Scholar
• Sartelli M, Coccolini F, Kluger Y, et al. WSES/GAIS/SIS-E/WSIS/AAST global clinical pathways for patients with intra-abdominal infections. World J Emerg Surg. 2021;16(1):49. doi: 10.1186/s13017-021-00387-8.
   PubMed Web of Science ®Google Scholar
• Bailey JA, Virgo KS, DiPiro JT, et al. Aminoglycosides for intra-abdominal infection: equal to the challenge? Surg Infect. 2002;3(4):315–335. doi: 10.1089/109629602762539544.
   PubMedGoogle Scholar
• The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters [Internet] ; 2023 [cited 2023 July 02]. Available from: http://www.eucast.org.
   Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing. Gentamicin: rationale for the EUCAST clinical breakpoints diameters [Internet]; 2023 [cited 2023 July 02]. Available from: http://www.eucast.org.
   Google Scholar
• Vidal L, Gafter-Gvili A, Borok S, et al. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2007;60(2):247–257. doi: 10.1093/jac/dkm193.
   PubMed Web of Science ®Google Scholar
• Hyle EP, Lipworth AD, Zaoutis TE, et al. Risk factors for increasing multidrug resistance among extended-spectrum betalactamase-producing Escherichia coli and Klebsiella species. Clin Infect Dis. 2005;40(9):1317–1324. doi: 10.1086/429239.
   PubMed Web of Science ®Google Scholar
• Lee OS, Lee ES, Park Young S, et al. Reduced use of third-generation cephalosporins decreases the acquisition of extended-spectrum beta-lactamase producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2004;25(10):832–837. doi: 10.1086/502304.
   PubMed Web of Science ®Google Scholar
• Martínez JA, Aguilar J, Almela M, et al. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. in patients with bacteraemia. J Antimicrob Chemother. 2006;58(5):1082–1085. doi: 10.1093/jac/dkl367.
   PubMed Web of Science ®Google Scholar
• Štrumbelj I, Pirš M, Berce I, et al. Slovenska komisija za ugotavljanje občutljivosti za protimikrobna zdravila (SKUOPZ): pregled občutljivosti bakterij za antibiotike – Slovenija 2016 diameters [Internet]; 2016 [cited 2023 July 27]. Available from: http://www.imi.si/strokovnazdruzenja/skuopz/dokumenti/Pregledobutljivosti2016SKUOPZ97896194044231.pdf.
   Google Scholar
• Cronin RE. Aminoglycoside nephrotoxicity: pathogenesis and prevention. Clin Nephrol. 1979;11(5):251–256.
   PubMed Web of Science ®Google Scholar
• Di Saverio S, Podda M, De Simone B, et al. Diagnosis and treatment of acute appendicitis: 2020 update of the WSES Jerusalem guidelines. World J Emerg Surg. 2020;15(1):27. doi: 10.1186/s13017-020-00306-3.
   PubMed Web of Science ®Google Scholar
• Markotic F, Grgic S, Poropat G, et al. Antibiotics for adults with acute cholecystitis or acute cholangitis or both. Cochrane Database Syst Rev. 2020;2020(6):CD013646.
   Google Scholar
• Gomi H, Solomkin JS, Schlossberg D, et al. Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2018;25(1):3–16. doi: 10.1002/jhbp.518.
   PubMed Web of Science ®Google Scholar
• Wickham H, Averick M, Bryan J, et al. Welcome to the tidyverse. JOSS. 2019;4(43):1686. doi: 10.21105/joss.01686.
   Google Scholar
• Heinzen E, Sinnwell J, Atkinson E, et al. An arsenal of 'R' functions for large-scale statistical summaries; R package version 3.6.3 [Internet]; 2021 [cited Sep 2]. Available from: https://CRAN.R-project.org/package=arsenal.
   Google Scholar
• Patil I. Visualizations with statistical details: the ‘ggstatsplot’ approach. JOSS. 2021;6(61):3167. doi: 10.21105/joss.03167.
   Google Scholar
• Gallaher JR, Charles A. Acute cholecystitis: a review. JAMA. 2022;327(10):965–975. doi: 10.1001/jama.2022.2350.
   PubMed Web of Science ®Google Scholar
• CholeS Study Group, Griffiths E, Vohra R. Cholecystectomy for cholecystitis: delayed surgery minimises conversion and 30 day complication rate. HPB. 2016; 18(2):e673. doi: 10.1016/j.hpb.2016.01.028.
   Google Scholar
• Fugazzola P, Cobianchi L, Di Martino M, et al. Prediction of morbidity and mortality after early cholecystectomy for acute calculous cholecystitis: results of the S.P.Ri.M.A.C.C. Study. World J Emerg Surg. 2023; Mar 1818(1):20. doi: 10.1186/s13017-023-00488-6.
   PubMed Web of Science ®Google Scholar
• Patel SV, Nanji S, Brogly SB, et al. High complication rate among patients undergoing appendectomy in Ontario: a population-based retrospective cohort study. Can J Surg. 2018;61(6):412–417. doi: 10.1503/cjs.011517.
   PubMed Web of Science ®Google Scholar
• Sartelli M, Baiocchi GL, Di Saverio S, et al. Prospective observational study on acute appendicitis worldwide (POSAW). World J Emerg Surg. 2018;13(1):19. doi: 10.1186/s13017-018-0179-0.
   PubMedGoogle Scholar
• Cho JY, Ho-Seong H, Yoo-Seok Y, et al. Risk factors for acute cholecystitis and a complicated clinical course in patients with symptomatic cholelithiasis. Arch Surg. 2010;145(4):329–333. doi: 10.1001/archsurg.2010.35.
   PubMedGoogle Scholar
• Margenthaler JA, Longo WE, Virgo KS, et al. Risk factors for adverse outcomes after the surgical treatment of appendicitis in adults. Ann Surg. 2003;238(1):59–66. doi: 10.1097/01.SLA.0000074961.50020.f8.
   PubMed Web of Science ®Google Scholar
• Yi NJ, Han HS, Min SK. The safety of a laparoscopic cholecystectomy in acute cholecystitis in high-risk patients older than sixty with stratification based on ASA score. Minim Invasive Ther Allied Technol. 2006;15(3):159–164. doi: 10.1080/13645700600760044.
   PubMed Web of Science ®Google Scholar
• Herzog T, Chromik AM, Uhl W. Treatment of complicated intra-abdominal infections in the era of multi-drug resistant bacteria. Eur J Med Res. 2010;15(12):525–532. doi: 10.1186/2047-783x-15-12-525.
   PubMed Web of Science ®Google Scholar
• Mazuski JE, Tessier JM, May AK, et al. The surgical infection society revised guidelines on the management of intra-abdominal infection. Surg Infect. 2017;18(1):1–76. doi: 10.1089/sur.2016.261.
   PubMed Web of Science ®Google Scholar
• Montravers P, Dupont H, Leone M, et al. Guidelines for management of intra-abdominal infections. Anaesth Crit Care Pain Med. 2015;34(2):117–130. doi: 10.1016/j.accpm.2015.03.005.
   PubMed Web of Science ®Google Scholar
• Fuks D, Cossé C, Régimbeau JM. Antibiotic therapy in acute calculous cholecystitis. J Visc Surg. 2013;150(1):3–8. doi: 10.1016/j.jviscsurg.2013.01.004.
   PubMed Web of Science ®Google Scholar
• Stankowicz MS, Ibrahim J, Brown DL. Once-daily aminoglycoside dosing: an update on current literature. Am J Health Syst Pharm. 2015;72(16):1357–1364. doi: 10.2146/ajhp140564.
   PubMed Web of Science ®Google Scholar
• Barclay ML, Kirkpatrick CM, Begg EJ. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? Clin Pharmacokinet. 1999;36(2):89–98. doi: 10.2165/00003088-199936020-00001.
   PubMed Web of Science ®Google Scholar
• Drusano GL, Ambrose PG, Bhavnani SM, et al. Back to the future: using aminoglycosides again and how to dose them optimally. Clin Infect Dis. 2007; 45(6):753–760. doi: 10.1086/520991.
   PubMed Web of Science ®Google Scholar
• Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother. 1999;43(7):1549–1555. doi: 10.1128/AAC.43.7.1549.
   PubMed Web of Science ®Google Scholar
• Mingeot-Leclercq MP, Tulkens PM. Aminoglycosides: nephrotoxicity. Antimicrob Agents Chemother. 1999;43(5):1003–1012. doi: 10.1128/AAC.43.5.1003.
   PubMed Web of Science ®Google Scholar
• Prins JM, Weverling GJ, van Ketel RJ, et al. Circadian variations in serum levels and the renal toxicity of aminoglycosides in patients. Clin Pharmacol Ther. 1997;62(1):106–111. doi: 10.1016/S0009-9236(97)90156-9.
   PubMed Web of Science ®Google Scholar
• Grayson ML, Cosgrove S, Crowe S, et al. Kucers’ the use of antibiotics. Boca Raton: CRC Press; 2017.
   Google Scholar